백신 시장 : 유형별, 백신 배합별, 질환별, 백신 분류별, 투여 경로별, 투여량별, 연령층별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Vaccines Market is projected to grow by USD 152.31 billion at a CAGR of 7.76% by 2032.

Vaccines Executive Summary

Vaccines remain one of the highest-impact health technologies, preventing an estimated 3.5 million to 5 million deaths every year, according to the World Health Organization. The vaccines landscape spans pediatric immunization, adult boosters, travel vaccines, maternal vaccination, therapeutic cancer vaccines, and epidemic preparedness, creating a broad industry shaped by public procurement, private innovation, and global health security needs.

Demand is being driven by routine immunization recovery after COVID-19 disruptions, rising use of newer platforms such as mRNA, viral vectors, recombinant proteins, and conjugate technologies, expanded human papillomavirus and pneumococcal programs, and stronger government stockpiling for pandemic and outbreak response. WHO and UNICEF estimates also show persistent access gaps, including 14.5 million zero-dose children in 2023, making coverage recovery and equitable delivery central to long-term vaccine strategy. For industry leaders, success depends on evidence-based portfolio prioritization, resilient supply chains, regulatory agility, and access models that improve immunization coverage while sustaining commercial performance.

Transformative Shifts in the Vaccines Landscape

The vaccine industry is shifting from a primarily pediatric and seasonal business toward a life-course immunization model. Aging populations are increasing demand for influenza, pneumococcal, shingles, respiratory syncytial virus, and COVID-19 vaccines, while maternal immunization is gaining policy support as a way to protect infants before they are eligible for direct vaccination.

Technology is also reshaping competition. mRNA platforms demonstrated global scalability during the COVID-19 response, and developers are now applying nucleic acid, recombinant protein, conjugate, viral-vector, and combination approaches to influenza, RSV, oncology, and emerging infectious disease vaccines. At the same time, governments are emphasizing domestic manufacturing, fill-finish capacity, cold-chain resilience, genomic surveillance, and faster regulatory pathways to reduce dependence on concentrated supply hubs and strengthen epidemic readiness.

Cumulative Impact of Artificial Intelligence on Vaccines

Artificial intelligence is becoming a practical accelerator across vaccine discovery, clinical development, manufacturing, and pharmacovigilance. AI-enabled antigen design, protein structure modeling, epitope prediction, and immune-response simulation can help narrow candidate selection before costly trials. In clinical operations, analytics can improve site selection, participant recruitment, protocol optimization, and real-time safety monitoring.

The cumulative impact is faster cycle times and more targeted investment decisions, but responsible adoption is essential. Vaccine developers must validate AI outputs against laboratory and clinical evidence, protect patient data, reduce model bias, and maintain transparent regulatory documentation. Used well, AI can strengthen pandemic readiness, optimize strain selection, improve demand forecasting, enhance quality control, and improve post-market signal detection without replacing established scientific and regulatory standards.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific is central to vaccine growth because of its population scale, expanding middle class, large birth cohorts, and manufacturing depth in China, India, Japan, South Korea, and Australia. The region is also shaped by high infectious-disease surveillance needs, national immunization expansion, and public investment in biotechnology capacity. North America remains a leading innovation and commercialization hub, supported by the U.S. biomedical research ecosystem, advanced regulatory pathways, robust adult immunization infrastructure, and coordinated public-health guidance in the United States and Canada.

Latin America shows rising demand for pediatric, HPV, influenza, dengue, and outbreak-response vaccines, with Brazil and Mexico anchoring public immunization programs and regional manufacturing ambitions. Europe combines mature vaccination programs with strong regulatory oversight through the European Medicines Agency and national technical advisory groups, while also prioritizing adult immunization, pharmacovigilance, antimicrobial-resistance prevention through vaccination, and supply resilience following pandemic-era procurement lessons.

The Middle East is investing in health security, procurement modernization, digital immunization systems, and domestic biologics capacity, particularly across high-income Gulf markets that are expanding preventive care and travel-related vaccination infrastructure. Africa represents both an urgent coverage opportunity and a long-term manufacturing priority, as the African Union and Africa CDC support expanded local vaccine production, stronger cold-chain systems, improved last-mile delivery, and more resilient supply networks to reduce dependence on imported vaccines.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN markets are expanding vaccine demand through sizable birth cohorts, school-based immunization programs, travel recovery, dengue prevention priorities, and stronger pandemic preparedness, while regional procurement approaches still vary widely by country income, financing structures, and health system capacity. The GCC is prioritizing immunization modernization, digital health records, life-course vaccination, and strategic purchasing, creating opportunities for adult vaccines, travel vaccines, and public-private supply partnerships.

The European Union remains influential through centralized regulatory standards, joint procurement experience, pharmacovigilance coordination, and health security planning under regional preparedness frameworks. BRICS economies combine large population needs with growing domestic manufacturing, public-sector procurement, and technology-transfer priorities, making them important for high-volume immunization delivery, localized production, and diversified global vaccine supply.

G7 countries lead in vaccine R&D financing, regulatory science, premium-market adoption, and preparedness funding, especially for adult, maternal, respiratory, and specialty vaccines. NATO members increasingly view vaccine availability as part of biodefense, military readiness, force health protection, and civil resilience, reinforcing the link between immunization, emergency preparedness, and national security.

Key Country Insights Across Major Vaccine Markets

The United States leads global vaccine innovation through deep capital markets, NIH-supported research, BARDA preparedness funding, ACIP guidance, and large commercial and public immunization channels. Canada emphasizes public procurement, national immunization guidance, and equitable access across provinces and territories, while Mexico combines public-sector demand with regional manufacturing potential and cross-border disease surveillance priorities. Brazil is a major Latin American anchor through its National Immunization Program, large public-sector purchasing role, and established public vaccine production capabilities.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are mature vaccine markets with strong regulatory systems, adult immunization needs, public purchasing mechanisms, and established pharmacovigilance practices. The United Kingdom has a prominent national immunization advisory structure and clinical research capacity; Germany and France bring advanced biomedical ecosystems and strong public-health infrastructure; Italy and Spain continue to focus on pediatric, elderly, and regional coverage improvements. Russia maintains domestic vaccine capabilities and sovereign supply priorities. China and India are critical to global scale: China has a large domestic immunization base and expanding biotechnology capabilities, while India is one of the world's largest vaccine suppliers by volume and a key source for routine immunization programs in low- and middle-income countries.

Japan, Australia, and South Korea are high-value Asia-Pacific vaccine markets with strong quality standards, aging populations, and active life-science ecosystems. Japan's demographic profile supports demand for adult and elderly immunization, Australia is important for seasonal influenza surveillance and regional public-health preparedness, and South Korea is strengthening its role in advanced biomanufacturing, clinical research, and regional epidemic-response partnerships.

Actionable Recommendations for Vaccine Industry Leaders

Industry leaders should prioritize life-course immunization portfolios, including adult respiratory, maternal, adolescent, travel, and specialty vaccines, while protecting core pediatric franchises. Commercial plans should be aligned with national immunization technical advisory group evidence requirements, real-world effectiveness data, safety monitoring, and health-economic models that demonstrate avoided hospitalizations, productivity gains, and health-system savings.

Operationally, organizations should diversify antigen, adjuvant, vial, stopper, lipid nanoparticle, cold-chain, and fill-finish supply; build regional manufacturing partnerships; and invest in end-to-end supply visibility. Leaders should also embed AI governance, strengthen pharmacovigilance, support vaccine confidence campaigns, improve healthcare-provider education, and design access models for low- and middle-income countries through tiered pricing, pooled procurement, donation mechanisms, and technology transfer where appropriate.

Research Methodology

This executive summary is based on a structured review of verified public-health, regulatory, and industry evidence. Core sources include the World Health Organization, UNICEF, Gavi, the Vaccine Alliance, the U.S. Centers for Disease Control and Prevention, the European Medicines Agency, national immunization programs, public procurement documents, peer-reviewed literature, and publicly available government and institutional disclosures.

The analysis combines disease-burden trends, immunization coverage data, technology-platform developments, regulatory patterns, procurement dynamics, cold-chain requirements, and regional manufacturing priorities. Findings were synthesized to identify durable strategic themes rather than short-term fluctuations, with emphasis on evidence that is internationally recognized, reproducible, and relevant to vaccine developers, manufacturers, distributors, healthcare providers, policymakers, and investors.

Conclusion

The vaccines sector is entering a more complex but opportunity-rich phase. Routine immunization recovery, adult vaccine expansion, mRNA and recombinant-platform innovation, AI-assisted development, and health-security investment are reshaping how vaccines are discovered, manufactured, financed, regulated, and delivered.

Winning organizations will combine scientific excellence with access discipline. They will need to prove clinical value, scale reliably, navigate regional policy differences, and support public trust. As governments and healthcare systems continue to treat immunization as both preventive care and strategic preparedness, vaccines will remain central to global health outcomes and long-term life-science growth.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Vaccines Market, by Type

• 7.1. Inactivated Vaccines
• 7.2. Live-Attenuated Vaccines
• 7.3. Messenger RNA Vaccines
• 7.4. Subunit, Recombinant, Polysaccharide, & Conjugate Vaccines
• 7.5. Toxoid Vaccines
• 7.6. Viral Vector Vaccines

8. Vaccines Market, by Vaccine Combination

• 8.1. Mono-Valent Vaccines
• 8.2. Multi-Valent Vaccines

9. Vaccines Market, by Disease Indication

• 9.1. Infectious Disease Vaccines
  • 9.1.1. Influenza
  • 9.1.2. Hepatitis A & B
  • 9.1.3. Polio
  • 9.1.4. COVID-19
  • 9.1.5. Pneumococcal & Meningococcal Disease
  • 9.1.6. Human Papillomavirus HPV
  • 9.1.7. Rotavirus
  • 9.1.8. Dengue
  • 9.1.9. Malaria
  • 9.1.10. Rabies
• 9.2. Non-Infectious Disease Vaccines
  • 9.2.1. Cancer Vaccines
  • 9.2.2. Allergy Vaccines
  • 9.2.3. Alzheimer's Vaccines

10. Vaccines Market, by Vaccine Classification

• 10.1. Preventive Vaccines
• 10.2. Therapeutic Vaccines

11. Vaccines Market, by Route of Administration

• 11.1. Intramuscular
• 11.2. Intranasal
• 11.3. Oral
• 11.4. Subcutaneous

12. Vaccines Market, by Dosage

• 12.1. Multi Dose
• 12.2. Single Dose

13. Vaccines Market, by Age Group

• 13.1. Adult
• 13.2. Geriatric
• 13.3. Pediatric
  • 13.3.1. Infants
  • 13.3.2. Toddlers

14. Vaccines Market, by End User

• 14.1. Academic & Research Institutes
• 14.2. Hospitals & Clinics
• 14.3. Vaccination Centers

15. Vaccines Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Vaccines Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Vaccines Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. Pfizer Inc.
• 19.2. BioNTech SE
• 19.3. Sinovac Biotech Ltd.
• 19.4. Moderna, Inc.
• 19.5. Merck & Co., Inc.
• 19.6. GlaxoSmithKline PLC
• 19.7. Sanofi S.A.
• 19.8. Johnson & Johnson Services, Inc.
• 19.9. AstraZeneca PLC
• 19.10. Abbott Laboratories
• 19.11. Astellas Pharma Inc.
• 19.12. Bavarian Nordic A/S
• 19.13. Bharat Biotech Ltd.
• 19.14. Biological E. Limited
• 19.15. Blue Lake Biotechnology
• 19.16. Capricor Therapeutics, Inc.
• 19.17. Chongqing Zhifei Biological Products Co., Ltd.
• 19.18. CSL Limited
• 19.19. CureVac N.V.
• 19.20. Daiichi Sankyo Company, Limited.
• 19.21. Gennova Biopharmaceuticals Limited
• 19.22. Haffkine Bio-Pharmaceutical Corporation Ltd.
• 19.23. Incepta Pharmaceuticals Ltd.
• 19.24. Inovio Pharmaceuticals, Inc.
• 19.25. Novavax, Inc.
• 19.26. Serum Institute of India Pvt. Ltd.
• 19.27. Takeda Pharmaceutical Company Limited
• 19.28. VBI Vaccines Inc.
• 19.29. Versatope Therapeutics
• 19.30. Zydus Lifesciences Limited